nilotinib: Clinical Trials

83 trials of nilotinib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

49 completed, 12 terminated, 7 active not recruiting, 6 recruiting. 83 Phase 2, 12 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 283Completed 49, Terminated 12, Active not recruiting 7, Recruiting 6, Unknown 5, Withdrawn 3, Not yet recruiting 1
Phase 112Completed 6, Terminated 3, Unknown 2, Withdrawn 1
Phase 31Completed 1

Follow nilotinib: new trials by email Literature Review of nilotinib trials Research Report on nilotinib

Trials (filtered) newest first · largest first

All 83 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML
Asciminib add-on, Imatinib, Dasatinib - Ph+ Acute Lymphoblastic Leukemia (Ph+ALL), Blastic Transformation of Chronic Myeloid Leukemia
Phase 2Not yet recruitingThe University of Hong Kong452026-03-302026-03-25
PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML
Asciminib, Nilotinib - CML, Chronic Phase, Chronic Myeloid Leukemia, Chronic Phase
Phase 2RecruitingGruppo Italiano Malattie EMatologiche dell'Adulto1602025-06-262025-07-08
Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial
Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
Phase 2Active not recruitingNational Cancer Institute (NCI)402023-07-142026-08-04
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Alpelisib, Binimetinib, Biopsy Procedure - Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8
Phase 2RecruitingNational Cancer Institute (NCI)29002023-04-072026-11-12
Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis
Paclitaxel, Nilotinib, ECG - Gynecologic Cancer, Gynecologic Neoplasms
Phase 2CompletedNational Cancer Institute (NCI)212022-10-132026-06-25
Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
Asciminib 40 MG, Asciminib 40 MG Twice Daily, Asciminib 80 MG daily - Chronic Phase Chronic Myelogenous Leukemia
Phase 2RecruitingMedical College of Wisconsin512021-11-112026-08-25
KRT-232 and TKI Study in Chronic Myeloid Leukemia
KRT-232, Dasatinib, Nilotinib - Chronic Myeloid Leukemia
Phase 1 / Phase 2UnknownKartos Therapeutics, Inc.1092021-05-072022-03-21
Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population
Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Withdrawal, Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Re-initiation - Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission
Phase 2Active not recruitingBaylor College of Medicine172020-12-222026-05-04
Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Eicosapentaenoic Acid, Tyrosine kinase inhibitor - Chronic Myeloid Leukemia, Chronic Phase
Phase 1 / Phase 2TerminatedMilton S. Hershey Medical Center12020-09-142022-07-01
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
Nilotinib and Paclitaxel - Neoplasms
Phase 2RecruitingNational Cancer Institute (NCI)822020-08-242026-11-09
Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients with Chronic Myeloid Leukemia
Imatinib withdrawal, Dasatinib, Nilotinib - Chronic Myeloid Leukemia, Chronic Phase, Withdrawal;Drug
Phase 2Active not recruitingMasaryk University1502020-06-162024-11-26
A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib)
Imatinib, Nilotinib, Dasatinib - Chronic Myeloid Leukemia, Chronic Myeloid Leukemia in Remission
Phase 2UnknownNational Research Center for Hematology, Russia1002020-01-152020-10-08
A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase
HQP1351, Hydroxyurea or Interferon-based therapy, Homoharringtonine - Chronic Myeloid Leukemia, Chronic Phase
Phase 2CompletedAscentage Pharma Group Inc.1442019-10-212025-03-03
Frontline Asciminib Combination in Chronic Phase CML
Imatinib, Nilotinib 300 mg, Dasatinib - Chronic Myeloid Leukemia
Phase 2Active not recruitingUniversity of Jena1252019-08-192026-08-18
Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Dementia With Lewy Bodies
Placebo oral capsule, Nilotinib Oral Capsule - Dementia With Lewy Bodies
Phase 2CompletedGeorgetown University432019-07-012026-06-12
Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
Dasatinib, Imatinib Mesylate, Laboratory Biomarker Analysis - Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Minimal Residual Disease
Phase 2Active not recruitingECOG-ACRIN Cancer Research Group402019-06-262026-09-15
A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia
Nilotinib, Asciminib - Chronic Myeloid Leukemia
Phase 2TerminatedNovartis Pharmaceuticals1352019-03-222026-07-13
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
Asciminib add-on, Imatinib, Nilotinib - CML, Chronic Myelogenous Leukemia
Phase 2CompletedNovartis Pharmaceuticals1042018-11-222026-04-21
Effect of Nilotinib in Cerebellar Ataxia Patients
Nilotinib - Ataxia, Cerebellar, Ataxia, Progressive
Phase 2CompletedSeoul National University Hospital702018-11-192021-09-29
Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia
Bosutinib, Dasatinib, Laboratory Biomarker Analysis - Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Phase 2Active not recruitingSWOG Cancer Research Network812018-10-242025-12-18

Showing 20 of 83. Sign in to see all of them.

Conditions studied

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (39)  ·  Leukemia, Myeloid, Chronic-Phase (15)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (9)  ·  Leukemia (7)  ·  Gastrointestinal Stromal Tumors (6)  ·  Neoplasm Metastasis (5)  ·  Blast Crisis (4)  ·  Leukemia, Myeloid, Acute (3)  ·  Melanoma (3)  ·  Neoplasms (3)  ·  Hematologic Diseases (2)  ·  Leukemia, Myeloid, Accelerated Phase (2)  ·  Ovarian Neoplasms (2)  ·  Recurrence (2)  ·  Synovitis, Pigmented Villonodular (2)

Sponsors

Novartis Pharmaceuticals (18)  ·  Gruppo Italiano Malattie EMatologiche dell'Adulto (4)  ·  National Cancer Institute (NCI) (4)  ·  University Health Network, Toronto (3)  ·  Centre Leon Berard (2)  ·  Fox Chase Cancer Center (2)  ·  Fred Hutchinson Cancer Center (2)  ·  Georgetown University (2)  ·  M.D. Anderson Cancer Center (2)  ·  Mayo Clinic (2)  ·  Medical College of Wisconsin (2)  ·  Amsterdam UMC, location VUmc (1)  ·  Andrew J. Wagner, MD, PhD (1)  ·  Ascentage Pharma Group Inc. (1)  ·  Assistance Publique - Hôpitaux de Paris (1)

Countries

United States (37)  ·  France (14)  ·  Italy (13)  ·  Germany (11)  ·  Spain (11)  ·  Canada (9)  ·  Netherlands (9)  ·  South Korea (9)  ·  United Kingdom (9)  ·  Japan (7)  ·  Poland (6)  ·  Belgium (5)  ·  Denmark (5)  ·  Israel (5)  ·  Russia (5)

Top investigators

Ehab Atallah, MD (2)  ·  Fernando L Pagan, MD (2)  ·  Margaret von Mehren, MD (2)  ·  Abhijit Guha (1)  ·  Alice P Chen, M.D. (1)  ·  Amer Zeidan (1)  ·  Andrew Grigg, MBBS, MD, FRACP, FRCPA (1)  ·  Andrew J. Wagner, MD, PhD (1)  ·  Andrew M Blakely, M.D. (1)  ·  Anna Turkina, Professor (1)  ·  Anne Hansen Ree, Prof. MD PhD (1)  ·  Aref Al-Kali (1)  ·  Aref Al-Kali, M.D. (1)  ·  Arnon Nagler, MD (1)

Results publications

PMID 17715389, PMID 25361995, PMID 16775235, PMID 18048643, PMID 19822896, PMID 21098399, PMID 21456006, PMID 21478667, PMID 21508120, PMID 23065514, PMID 23547655, PMID 23620574, PMID 23666528, PMID 24057647, PMID 25387866, PMID 25695690, PMID 26002753, PMID 26113419, PMID 26283632, PMID 26687426, PMID 27434297, PMID 28042454, PMID 28298564, PMID 28327988, PMID 28566209, PMID 28601294, PMID 28835440, PMID 29459949, PMID 29486663, PMID 29571946, PMID 29609532, PMID 29996726, PMID 30026110, PMID 30885996, PMID 31201085, PMID 31511239, PMID 31841599, PMID 32208873, PMID 32499241, PMID 33180106, PMID 33513367, PMID 34309636, PMID 34786477, PMID 35086719, PMID 35598186, PMID 35932628, PMID 35943168, PMID 35982483, PMID 36624161, PMID 36870947

NIH funding

U10CA180820 (3), 2009 (2), P30CA015704 (2), 2015 (1), 2018 (1), P01CA018029 (1), P01CA078902 (1), P30CA015083 (1), U10CA180888 (1)